An Italian cost-effectiveness analysis of paclitaxel albumin (nab®-paclitaxel) plus gemcitabine vs gemcibatine alone for metastatic pancreatic cancer patients: The APICE study

被引：0
|
作者：
Lazzaro, C. [1 ]
Barone, C. [2 ]
Caprioni, F. [3 ]
Cascinu, S. [4 ]
Falcone, A. [5 ]
Maiello, E. [6 ]
Milella, M. [7 ]
Pinto, C. [8 ]
Reni, M. [9 ]
Tortora, G. [10 ]
机构：
[1] Studio Econ Sanit, Pharmacoecon, Milan, Italy
[2] Policlin Univ A Gemelli, UOC Oncol Med, Med Interna, Rome, Italy
[3] IST Ist Nazl Ric Canc, IRCCS AOU San Martino, Oncol Med 1, Genoa, Italy
[4] Azienda Osped Univ Policlin Modena, Med Oncol, Modena, Italy
[5] Azienda Osped Univ S Chiara, Dept Oncol Presidio Ospedaliero, Pisa, Italy
[6] IRCCS Casa Sollievo Sofferenza, Dept Hematol Oncol, San Giovanni Rotondo, Italy
[7] Ist Regina Elena, SC Oncol Med A, Rome, Italy
[8] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, SC Oncol, Reggio Emilia, Italy
[9] IRCCS San Raffaele, Med Oncol, Milan, Italy
[10] Azienda Osped Univ Integrata Verona Borgo Roma, Med Oncol, Verona, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw377.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1045P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A COST-UTILITY ANALYSIS OF NAB-PACLITAXEL (ABRAXANE) PLUS GEMCITABINE IN METASTATIC PANCREATIC CANCER IN SLOVAK REPUBLIC
    Stetka, R.
    Ondrusova, M.
    Psenkova, M.
    Pastorek, T.
    Salek, T.
    VALUE IN HEALTH, 2015, 18 (07) : A464 - A464
  • [32] Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Von Hoff, Daniel
    Wan, Yin
    Margunato-Debay, Sandra
    Botteman, Marc
    Goldstein, David
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1389 - 1396
  • [33] Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
    Wenjie Liu
    Yuting Fang
    Chao Zhang
    Midan Xiang
    Lijuan Qi
    Aijiang Su
    Yongkun Sun
    BMC Gastroenterology, 25 (1)
  • [34] Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
    Carrato, Alfredo
    Garcia, Pilar
    Lopez, Rafael
    Macarulla, Teresa
    Rivera, Fernando
    Sastre, Javier
    Gostkorzewicz, Joana
    Benedit, Patricia
    Perez-Alcantara, Ferran
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (04) : 579 - 589
  • [35] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.
    Ingram, Myles
    Lauren, Brianna N.
    Pumpalova, Yoanna S.
    Manji, Gulam Abbas
    Bates, Susan Elaine
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Borazanci, Erkut
    Schroeder, Katy
    Jameson, Gayle S.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [38] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [39] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [40] COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX AND NAB-PACLITAXEL (ABARAXANE) PLUS GEMCITABINE FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC CANCER FROM THE US SOCIETAL PERSPECTIVE
    Cheng, W.
    Hay, J. W.
    VALUE IN HEALTH, 2016, 19 (03) : A153 - A153
12345